Poly-(ethylene glycol) modified gelatin nanoparticles for sustained delivery of the anti-inflammatory drug Ibuprofen-Sodium: An in vitro and in vivo analysis

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 9, Issue 6, 2013, Pages 818-828

  Narayanan, Dhanya ^a   Geena, M G ^a   Lakshmi, H ^a   Koyakutty, Manzoor ^a   Nair, Shantikumar ^a   Menon, Deepthy ^a  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Gelatin nanoparticles; Hemocompatibility; Ibuprofen Sodium; Pharmacokinetics; Poly(ethylene glycol)

Indexed keywords

ANTI-INFLAMMATORY DRUGS; CLINICAL APPLICATION; DESOLVATION PROCESS; ENTRAPMENT EFFICIENCY; GELATIN NANOPARTICLES; HEMOCOMPATIBILITY; HISTOLOGICAL ANALYSIS; PRECLINICAL STUDIES;

BIOCHEMISTRY; BIOCOMPATIBILITY; ETHYLENE GLYCOL; MAMMALS; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; PHARMACOKINETICS; POLYETHYLENE GLYCOLS; SODIUM;

DRUG PRODUCTS;

GELATIN; IBUPROFEN; MACROGOL; NANOPARTICLE; ANTIINFLAMMATORY AGENT; MACROGOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIODEGRADABILITY; CHEMICAL COMPOSITION; CHEMICAL MODIFICATION; CHEMICAL REACTION; CONTROLLED STUDY; CYTOKINE RELEASE; DESOLVATION; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG STABILITY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; RAT; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; CHEMISTRY; INFLAMMATION;

ANTI-INFLAMMATORY AGENTS; DRUG DELIVERY SYSTEMS; GELATIN; HUMANS; IBUPROFEN; INFLAMMATION; NANOPARTICLES; PARTICLE SIZE; POLYETHYLENE GLYCOLS;

EID: 84880760990     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.02.001     Document Type: Article

References (47)

1. Munir A., Nasr E., Jun-Ming Z. Nonopioid analgesics. Med Clin N Am 2007, 91:97-111.
2. Melarange R., Blower P., Spangler R. Comparison of the anti-inflammatory activity and gastrointestinal irritancy of nabumetone, ibuprofen, and diclofenac in rats following chronic administration. Eur J Rheumatol Inflamm 1994, 14:23-27.
3. Jones R., Rubin G. Gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Med 2008, 121:464-474.
4. Cioli V., Putzolu S., Rossi V., Scorza B.P., Corradino C. The role of direct tissue contact in the production of gastrointestinal ulcers by anti-inflammatory drugs in rats. Toxicol Appl Pharmacol 1979, 50:283-289.
5. O'Laughlin J., Hoftiezer J., Ivey K. Effect of aspirin on the human stomach in normals: Endoscopic comparison of damage produced one hour, 24hours and 2weeks after administration. Scand J Gastroenterol 1980, 16:211.
6. Beck E.W., Schneider H., Dietzel K., Nuernberg B., Brune K. Gastrointestinal ulceration induced by anti-inflammatory drugs in rats. Arch Toxicol 1990, 64:210-217.
7. Jan H., Bercem D., Clemens G., Tim G., Gisbert S., Meike H., et al. Structural properties of so-called NSAID-phospholipid-complexes. Eur J Pharm Sci 2011, 44:103-116.
8. Torchilin V.P., Lukyanov A.N., Gao Z., Papahadjopoulos-Sternberg B. Targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci 2003, 100:6039-6044.
9. Mrinmoy D.E., Ghosh S., Rotello M. Applications of nanoparticles in biology. Adv Mater 2008, 20:1-17.
10. Soppimath K.S., Aminabhavia T.M., Kulkarnia A.R., Rudzinski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J Controlled Release 2001, 70:1-20.
11. Mohanraj V.J., Chen Y. Nanoparticles - a review. Trop J Pharm Res 2006, 5:561-573.
12. Amir H.F., Peter W. Nanoparticles in cellular drug delivery. Bioorg Med Chem 2009, 17:2950-2962.
13. Djagny V.B., Wang Z., Xu S. Gelatin: a valuable protein for food and pharmaceutical industries: review. Crit Rev Food Sci Nutr 2001, 41:481-492.
14. Schwick H.G., Heide K. Immunochemistry and immunology of collagen and gelatin. Bibl Hematol 1969, 33:111-125.
15. Goldie K., Mansoor A. Tumor-targeted gene delivery using Poly(ethylene glycol)-modified Gelatin Nanoparticles: in vitro and in vivo studies. Pharm Res 2005, 22:951-961.
16. Rakesh K., Ramesh C.N., Meenakshi D., Jayanta K.P. In-vitro and in-vivo study of indomethacin loaded gelatin nanoparticles. J Biomed Nanotechnol 2011, 7:325-333.
17. Owens D.E., Peppas N. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006, 307:93-102.
18. Zahr A.S., Davis C.A., Pishko M.V. Macrophage uptake of core-shell nanoparticles surface modified with poly(ethylene glycol). Langmuir 2006, 2:8178-8185.
19. Coester C.J., Langer K., Van B.H., Kreuter J. Gelatin nanoparticles by two step desolvation-a new preparation method, surface modifications and cell uptake. J Microencapsulation 2000, 17:187-193.
20. Harris S.M., Jaweria T., Hamid A.M., Rabia I.Y. Evaluation of drug release kinetics from ibuprofen matrix tablets using HPMC. Pak J Pharm Sci 2006, 19:119-124.
21. Harboe M. A method for determination of hemoglobin in plasma by near-ultraviolet spectrophotometry. Scand J Clin Lab Invest 1959, 11:66-70.
22. Banu S.Z., González F., Nakissa S., Marina A.D. Nanoparticles and the immune system. Endocrinology 2010, 151:458-465.
23. Abdullah G.Z., Abdulkarim M.F., Salman I.M., Ameer O.Z., Chtneni M., Mahdi E.S., et al. HPLC method modification and validation for quantification of ibuprofen. Int J Adv Pharm Sci 2010, 1:404-409.
24. Manjunath K., Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Controlled Release 2005, 107:215-228.
25. Saano V., Paronen P., Peura P., Vidgren M. Relative pharmacokinetics of three oral 400mg ibuprofen dosage forms in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1991, 29:381-385.
26. Tatsiana G.S., Shantanu S.B., Pranitha V., Joshua J.S., Rebecca L.B., James A.C., et al. Layer-by-layer-coated gelatin nanoparticles as a vehicle for delivery of natural polyphenols. ACS Nano 2009, 3:1877-1885.
27. Weilong W., Xiaoxi Y., Yutang F., Jing D., Jinyue Y. Preparation and thermal properties of polyethylene glycol/expanded graphite blends for energy storage. Appl Energ 2009, 86:1479-1483.
28. Ritger P.L., Peppas N.A. A simple equation for description of solute release I, Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J Controlled Release 1987, 5:23-36.
29. Kamath S., Blann A.D., Lip G.Y.H. Platelet activation: assessment and quantification. Eur Heart J 2001, 22:1561-1571.
30. Marina A.D., Parag A., Jennifer B.H., Scott E.M. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm 2008, 5:487-495.
31. Anand B.D., Renu S.D., Ramesh P. In vivo pharmacokinetic and tissue distribution studies in mice of alternative formulations for local and systemic delivery of paclitaxel: gel, film, prodrug, liposomes and micelles. Curr Drug Delivery 2005, 2:35-44.
32. Soo-Jin C., Jae-Min O., Jin-Ho C.J. Biocompatible nanoparticles intercalated with anticancer drug for target delivery: pharmacokinetic and biodistribution study. J Nanosci Nanotechnol 2010, 10:2913-2916.
33. Sörgel F., Fuhr U., Minic M., Siegmund M., Maares J., Jetter A. Pharmacokinetics of ibuprofen sodium dihydrate and gastrointestinal tolerability of short-term treatment with a novel, rapidly absorbed formulation. Int J Clin Pharmacol Ther 2005, 43:140-149.
34. Adams S.S., Bough R.G., Cliffe E.E., Lessel B., Mills R.F.N. Absorption, distribution and toxicity of ibuprofen. Toxicol Appl Pharmacol 1969, 15:310-330.
35. Shirzad A., Yuan H., Hua C., Steve M.Q., Douglas A., Wilson R. Optimization of a two-step desolvation method for preparing gelatin nanoparticles and cell uptake studies in 143B osteosarcoma cancer cells. J Pharm Pharmaceut Sci 2006, 9:124-132.
36. Wei Y., Jasmine T., Dave A.M., Jiping Z., Jason T.M., Keith P.J. High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. Int J Pharm 2008, 361:177-188.
37. Gautam S., Mahaveer S. Review: in-vitro drug release characterization models. Int J Pharm Stud Res 2011, 2:77-84.
38. 111In-octreotide in mice and rats. J Nucl Med 2006, 47:528-533.
39. Waters E.T. A comparison of Isinglass and gelatin as blood substitutes. Can Med Assoc J 1941, 45:395-398.
40. Sinha D., Seaman F.S., Walsh P.N. Role of calcium ions and the heavy chain of factor XIa in the activation of human coagulation factor IX. Biochemistry 1987, 26:3768-3775.
41. Pattani A., Patravale V.B., Panicker L., Potdar P.D. Immunological effects and membrane interactions of chitosan nanoparticles. Mol Pharm 2009, 6:345-352.
42. Anusha A., Parwathy C., Aparna R.S., Chaitanya K.K., Archana P.R., Deepthy M., et al. Development and haematotoxicological evaluation of doped hydroxyapatite based multimodal nanocontrast agent for near-infrared, magnetic resonance and X-ray contrast imaging. Nanotoxicology 2012, 6:652-666.
43. Andre E.N., Lutz M., Darrell V., Tian X., Eric M.V.H., Somasundaran P. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 2009, 8:543-557.
44. Tommy C., Iseult L., Stina L., Tord B., Eva T., Hanna N., et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci 2007, 104:2050-2055.
45. Harris J.M., Martin N.E., Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001, 40:539-551.
46. Tang G.P., Zeng J.M., Gao S.J., Ma Y.X., Shi L., Li Y., et al. Polyethylene glycol modified polyethylenimine for improved CNS gene transfer: effects of PEGylation extent. Biomaterials 2003, 24:2351-2362.
47. Lakshmi S.N., Cato T.L. Biodegradable polymers as biomaterials. Prog Polym Sci 2007, 32:762-798.